34results about How to "Avoid off-target effects" patented technology

The present invention relates to a nucleic acid inducing RNA interference modified for preventing off-target, and a use thereof, and more specifically, to a nucleic acid inducing RNA interference, modified by replacing, by a spacer capable of no base pairing, 5' terminal and 3' terminal regions in at least one single strand of the double strand of the nucleic acid inducing RNA interference. The nucleic acid inducing RNA interference of the present invention can provide: a nucleic acid having a novel modified form for preventing an off-target effect generated when inhibiting the expression of a target gene by an RNA interference phenomenon; and a method for selectively inhibiting the expression of a target gene by using the same. In addition, the nucleic acid inducing RNA interference according to the present invention solves the inaccuracy and side effects due to off-target, which are the problems of a known nucleic acid inducing RNA interference, by providing a nucleic acid inducing RNA interference as a novel modified form having target selectivity and specificity by preventing an off-target effect while inhibiting the expression of a target gene, and thus can be used, without worries, in the research of a technique for inhibiting the expression of a gene and in gene therapy.

The present invention provides an anti-ErbB2 single chain antibody, a human ErbB2-targeting chimeric antigen receptor, a recombinant vector, a recombinant cell, and an application thereof, and pertains to the technical field of immunobiotherapy for tumors, where the anti-ErbB2 single chain antibody has an amino acid sequence depicted in SEQ ID No.1; the human ErbB2-targeting chimeric antigen receptor has an amino acid sequence depicted in SEQ ID No.3; the recombinant vector includes a gene encoding the chimeric antigen receptor and an initial vector; the recombinant cell includes a natural killer (NK) cell and the recombinant vector. The anti-ErbB2 single-chain antibody of the present invention is capable of recognizing tumor cell specifically, thereby, avoiding the off-target effects of the CAR-NK cells, and having excellent cytotoxixitc effects to tumor cell continuously; the recombinant cell is capable of having a higher cytotoxixity to tumor cell and reducing the risk of cytokine storm.

The invention provides a chimeric antigen receptor immune cell and a preparation method and application thereof. The expressed CAR molecule includes a signal peptide, a binding receptor of the coronavirus spike glycoprotein, a hinge region, a transmembrane domain, and a costimulatory structure. domain and signaling domain; the CAR molecule also includes secretory ACE2, which is connected to the carboxyl terminus of the signaling domain through a linking peptide; the immune cells expressing the CAR molecule have the ability to target and clear the cells infected by the new coronavirus, and Release secreted ACE2 molecules to competitively bind to the viral S protein to achieve allogeneic reinfusion to treat people infected with COVID-19 and prevent the transformation from mild to critically ill. It also has universal curative effect on other viruses bound by ACE2 receptors, and has strategic reserve value It provides new methods and ideas for the treatment of many major human diseases such as tumors and immune diseases.